BCRX - BioCryst Pharmaceuticals, Inc.
9.23 0.00 (0.00%)
After hours: 4:36PM EST
| Previous Close | 9.22 |
| Open | 9.17 |
| Bid | 8.24 x 3200 |
| Ask | 9.95 x 1200 |
| Day's Range | 8.92 - 9.34 |
| 52 Week Range | 4.25 - 9.71 |
| Volume | 550,094 |
| Avg. Volume | 679,817 |
| Market Cap | 1.012B |
| Beta (3Y Monthly) | 2.56 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.93 |
| Earnings Date | Feb 25, 2019 - Mar 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.29 |
- GlobeNewswire•14 days ago
BioCryst Appoints Steve Aselage to Board of Directors
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the company has appointed Steve Aselage to its board of directors. Mr. Aselage most recently served as chief executive officer of Retrophin Pharmaceuticals, a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease, which he joined in 2012. From 2005 to 2012, Mr. Aselage served as executive vice president and chief business officer of BioMarin.
- GlobeNewswire•16 days ago
BioCryst to Present at 37th Annual J.P. Morgan Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2019 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 37th Annual J.P. Morgan.
- GlobeNewswire•16 days ago
BioCryst Initiates Phase 1 Clinical Trial of Galidesivir
BioCryst Pharmaceuticals, Inc. (BCRX) today announced the dosing of the first subject in a randomized, placebo-controlled phase 1 clinical trial to evaluate intravenous (IV) galidesivir in healthy volunteers. The main goals of this trial are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of galidesivir in healthy subjects. BioCryst has global rights to galidesivir, a broad-spectrum antiviral drug in development to treat Marburg virus disease and Yellow Fever.
- Thomson Reuters StreetEvents•last month
Edited Transcript of BCRX earnings conference call or presentation 6-Nov-18 1:30pm GMT
Q3 2018 BioCryst Pharmaceuticals Inc Earnings Call
- Insider Monkey•last month
BioCryst Pharmaceuticals, Inc. (BCRX) Hedge Funds Are Snapping Up
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- GlobeNewswire•2 months ago
New Research Coverage Highlights Immunomedics, Surmodics, PDF Solutions, Stepan, Express Scripts Holding, and BioCryst Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors
BioCryst Pharmaceuticals, Inc. (BCRX) today announced that the company has appointed Theresa Heggie to its Board of Directors. At Shire, Ms. Heggie also built the EMEA rare disease business from $96 million to more than $750 million, and served as chief executive officer of Jerini, following Shire’s acquisition of the company, and its lead asset, Firazyr®, for the treatment of hereditary angioedema (HAE).
- GlobeNewswire•2 months ago
BioCryst Presents Data Highlighting the Rapid and Sustained Plasma Concentrations of BCX7353 in HAE Patients at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2018 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today presented data showing that an oral formulation of BCX7353 was rapidly.
- GlobeNewswire•2 months ago
BioCryst to Present at Upcoming Investor Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 08, 2018 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Jefferies London Healthcare.
- Zacks•2 months ago
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of -12.00% and -42.60%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
BioCryst: 3Q Earnings Snapshot
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 28 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
- GlobeNewswire•2 months ago
BioCryst Reports Third Quarter 2018 Financial Results
APeX-2 study enrollment completed, results on-track for Q2 2019 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced.
- GlobeNewswire•2 months ago
BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2018 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present three abstracts at the upcoming Annual.
- Zacks•3 months ago
Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q3 Earnings Expected to Decline
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•3 months ago
BioCryst to Report Third Quarter 2018 Financial Results on November 6
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2018 -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will report its third quarter 2018 financial.
- Zacks•3 months ago
Grifols (GRFS) Surges: Stock Moves 5.4% Higher
Grifols (GRFS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Market Realist•4 months agoWhat Sarepta Therapeutics’ Valuation Trend Indicates
Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter of 2018 compared to a net loss of $63.05 million in Q2 2017. Its net loss per share was $1.15 in the second quarter of 2017. Despite the surge in revenues, Sarepta’s net loss widened due to higher operating expenses, which increased from $98.35 million in the second quarter of 2017 to $176.96 million in the second quarter of 2018.
- Motley Fool•4 months ago
Here's Why BioCryst Pharmaceuticals Rose 21.3% in August
Believe it or not, share prices rose after the company announced a share offering.
- Benzinga•4 months ago
The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Biotech Stocks Hitting 52-week highs on Sept. 4) Aptinyx Inc (NASDAQ: APTX ) Becton Dickinson and Co ...
